|
|
Antibiotic is approved for Mycoplasma bovis treatmentPfizer Animal Health, New York, N.Y., recently announced DRAXXIN (tulathromycin) Injectable Solution recently received a control claim from the Food and Drug Administration for Mycoplasma bovis, one of the leading causes of bovine respiratory disease (BRD). The product is now the first and only antibiotic approved for the treatment and control in cattle at high risk of developing BRD for all of the four major BRD disease pathogens, including Mycoplasma bovis. The new label claim is significant, as more and more scientists, diagnosticians and veterinarians are recognizing the key role Mycoplasma bovis plays in causing illness and death loss in feedyard calves. A part of the BRD complex, Mycoplasma bovis is also a main contributor to the development and severity of lung lesions in cattle affected by BRD. In fact, studies published in the January 2006 Journal of Veterinary Diagnostics reports that Mycoplasma bovis was isolated in the lungs of 98 percent of cattle with chronic pneumonia, and 85 percent of cattle with acute pneumonia. For those chronically affected calves, the eventual outcome of Mycoplasma bovis has been permanent lung damage, reduced gain, death, or premature removal for markedly reduced salvage value. "In some classes of cattle, Mycoplasma bovis has grown to become one of our biggest concerns among respiratory pathogens," said Dr. Daniel Scruggs, DVM, DACVP, Pfizer Animal Health. "It may be difficult to recognize early in the disease process, consequently treatment may be delayed, resulting in less favorable recovery. "Not only are these chronically infected cattle less profitable, they also are excellent sources of infection for their pen mates, which tends to perpetuate and prolong the disease outbreak," Scruggs added. DRAXXIN offers a convenient, full course of therapy in a single dose and is indicated for the treatment and control in cattle at high risk of developing bovine respiratory disease caused by the four major BRD pathogens: Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. DRAXXIN is not for use in female dairy cattle 20 months of age or older or calves to be processed for veal. DRAXXIN has a pre-slaughter time of 18 days. For more information, call a local veterinarian or Pfizer Animal Health representative, or visit www.draxxin.com Date: 10/16/07
Copyright/Privacy
Copyright 1995-2012. High Plains Publishers, Inc. All rights reserved. Any republishing of these pages, including electronic reproduction of the editorial archives or classified advertising, is strictly prohibited. If you have questions or comments you can reach us at High Plains Journal 1500 E. Wyatt Earp Blvd., P.O. Box 760, Dodge City, KS 67801 or call 1-800-452-7171. Email: webmaster@hpj.com |
|
